Project Grant R21AI184166
Award Date 7/24/24
Completion Date 5/31/26
Dollars Obligated $648K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94110, USA
Similar Awards
- This $251,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support a clinical trial planning project focused on evaluating the use of adeno-associated virus (AAV)-delivered broadly neutralizing antibodies (bnAbs) to achieve durable control of HIV-1 in children after discontinuation of antiretroviral therapy (ART). The award to the University of Massachusetts Medical School will help develop a full...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $240,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University to conduct research on characterizing the HIV-1 viral reservoirs that persist even under antiretroviral therapy (ART). The 2-year project aims to identify the cellular sources and genetic diversity of the HIV-1 reservoirs, as well as study the sources and characteristics of the residual viremia...
- This $1,332,155 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to Emory University aims to conduct a systematic analysis of optimization strategies for broadly neutralizing antibody (BnAb) immunotherapy in the unique setting of postnatal HIV infection in infants. The key objectives are to: 1) Define how NF-kB pathway activation with BnAb administration during early ART impacts viral reservoir...
- This $812,810 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Emory University to generate highly differentiated natural killer (NK) cells and evaluate their synergistic effects with broadly neutralizing antibodies in reducing the SIV reservoir and establishing viral control in the absence of antiretroviral therapy (ART). The key objectives are to: 1) define...
- This Project Grant award of $800,389.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The proposed treatment combines soluble IL-15/IL-15RA-FC with a TGF-β pathway blockade and therapeutic vaccination to enhance and restore anti-viral immunity, leading to sustained viral remission...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $489,500.00 to The Children's Hospital of Philadelphia to investigate the cellular identity of the intact HIV reservoir. The key objectives are to: Test the hypothesis that CD4+ T cells with provirus in closed chromatin are transcriptionally distinct from cells with provirus in open chromatin (Aim 1). Test the hypothesis that cells with...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,554,273 to the Fred Hutchinson Cancer Center in Seattle, WA to assess the impact of oral pre-exposure prophylaxis (PrEP) on the pharmacokinetics of monoclonal antibodies and vaccine-induced antibodies among women vulnerable to HIV-1. The key objectives of this 4-year award are to: 1) Determine whether oral...
- This Project Grant award of $463,615.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) will fund a study titled "VIOLA: STUDY OF VIREMIA ON LONG-ACTING ANTIRETROVIRAL THERAPY WITH CABOTEGRAVIR AND RILPIVIRINE" at the University of California, San Francisco. The study aims to assess cabotegravir and rilpivirine concentrations and viral resistance mutations among people with HIV who experience virologic failure...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $492,980 to the University of Virginia (UVA) to investigate how variations in the HIV Rev-Rev Response Element (Rev-RRE) regulatory system impact viral transmission and latency. The project aims to define the role of Rev-RRE variation in sexual transmission, explore the contribution of the Rev-RRE axis to latency...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,414,502 to the University of North Carolina at Chapel Hill (UNC-CH) to conduct research on assessing the variability in antiretroviral (ARV) drug penetration within tissues as a potential factor contributing to the persistence of HIV during treatment. The research aims to leverage advanced imaging techniques,...